Toxic epidermal necrolysis and Stevens-Johnson syndrome
Top Cited Papers
Open Access
- 16 December 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 5 (1), 39
- https://doi.org/10.1186/1750-1172-5-39
Abstract
Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes. Both are rare, with TEN and SJS affecting approximately 1or 2/1,000,000 annually, and are considered medical emergencies as they are potentially fatal. They are characterized by mucocutaneous tenderness and typically hemorrhagic erosions, erythema and more or less severe epidermal detachment presenting as blisters and areas of denuded skin. Currently, TEN and SJS are considered to be two ends of a spectrum of severe epidermolytic adverse cutaneous drug reactions, differing only by their extent of skin detachment. Drugs are assumed or identified as the main cause of SJS/TEN in most cases, but Mycoplasma pneumoniae and Herpes simplex virus infections are well documented causes alongside rare cases in which the aetiology remains unknown. Several drugs are at "high" risk of inducing TEN/SJS including: Allopurinol, Trimethoprim-sulfamethoxazole and other sulfonamide-antibiotics, aminopenicillins, cephalosporins, quinolones, carbamazepine, phenytoin, phenobarbital and NSAID's of the oxicam-type. Genetic susceptibility to SJS and TEN is likely as exemplified by the strong association observed in Han Chinese between a genetic marker, the human leukocyte antigen HLA-B*1502, and SJS induced by carbamazepine. Diagnosis relies mainly on clinical signs together with the histological analysis of a skin biopsy showing typical full-thickness epidermal necrolysis due to extensive keratinocyte apoptosis. Differential diagnosis includes linear IgA dermatosis and paraneoplastic pemphigus, pemphigus vulgaris and bullous pemphigoid, acute generalized exanthematous pustulosis (AGEP), disseminated fixed bullous drug eruption and staphyloccocal scalded skin syndrome (SSSS). Due to the high risk of mortality, management of patients with SJS/TEN requires rapid diagnosis, evaluation of the prognosis using SCORTEN, identification and interruption of the culprit drug, specialized supportive care ideally in an intensive care unit, and consideration of immunomodulating agents such as high-dose intravenous immunoglobulin therapy. SJS and TEN are severe and life-threatening. The average reported mortality rate of SJS is 1-5%, and of TEN is 25-35%; it can be even higher in elderly patients and those with a large surface area of epidermal detachment. More than 50% of patients surviving TEN suffer from long-term sequelae of the disease.Keywords
This publication has 116 references indexed in Scilit:
- Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and IsraelJournal of the American Academy of Dermatology, 2008
- Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR StudyJournal of the American Academy of Dermatology, 2008
- Mycoplasma pneumoniae–induced Stevens-Johnson syndrome without skin lesions: Fact or fiction?Journal of the American Academy of Dermatology, 2005
- Comparison of Reporting of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Selective COX-2 InhibitorsDrug Safety, 2005
- Toxic Epidermal Necrolysis: Does Immunoglobulin Make a Difference?Journal of Burn Care & Rehabilitation, 2004
- Intracellular Localization of Keratinocyte Fas Ligand Explains Lack of Cytolytic Activity under Physiological ConditionsJournal of Biological Chemistry, 2003
- Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in ChildrenDrug Safety, 2002
- Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN?-treated cultured keratinocytesArchiv für dermatologische Forschung, 1995
- Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virusJournal of the American Academy of Dermatology, 1992
- Efficacy of cyclophosphamide in toxic epidermal necrolysisJournal of the American Academy of Dermatology, 1991